EP-104GI
EP-104IAR-102 (RESOLVE)
Phase 2 small_molecule active
Quick answer
EP-104GI for Eosinophilic Esophagitis is a Phase 2 program (small_molecule) at EUPRAXIA PHARMACEUTICALS INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- EUPRAXIA PHARMACEUTICALS INC.
- Indication
- Eosinophilic Esophagitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active